Scynexis (SCYX) Amortization of Deferred Charges (2013 - 2025)
Scynexis' (SCYX) quarterly Amortization of Deferred Charges came in at $312000.0 in Q1 2025, down 22.19% on a YoY basis from $401000.0 in Q1 2024, and down 32.76% quarter-over-quarter from $464000.0 in Q4 2024.
Powered by 
Analysis
Scynexis (SCYX) Amortization of Deferred Charges (2013 - 2025) Analysis & Trends
Scynexis (SCYX) has reported Amortization of Deferred Charges for 12 consecutive years, with $312000.0 the latest figure, recorded in Q1 2025.
- For the quarter ending Q1 2025, Amortization of Deferred Charges fell 22.19% year-over-year to $312000.0; the trailing twelve-month figure through Dec 2025 stood at $312000.0 (down 81.93% YoY), and the FY2025 full-year result was $312000.0, down 81.92% from the prior year.
- Amortization of Deferred Charges declined to $312000.0 in Q1 2025 per SCYX's latest filing, from $464000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $2.0 million in Q2 2023 and bottomed at $255000.0 in Q1 2023.
- Historically, Amortization of Deferred Charges has averaged $466823.5 across 5 years, with a median of $395000.0 in 2022.
- The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges jumped 374.58% in 2023, then plunged 78.93% in 2024.
- Over 5 years, Amortization of Deferred Charges stood at $366000.0 in 2021, then grew by 7.92% to $395000.0 in 2022, then fell by 4.3% to $378000.0 in 2023, then climbed by 22.75% to $464000.0 in 2024, then sank by 32.76% to $312000.0 in 2025.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $312000.0, $464000.0, and $441000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 312,000.00 |
| Dec 31, 2024 | 464,000.00 |
| Sep 30, 2024 | 441,000.00 |
| Jun 30, 2024 | 421,000.00 |
| Mar 31, 2024 | 401,000.00 |
| Dec 31, 2023 | 378,000.00 |
| Sep 30, 2023 | 360,000.00 |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 255,000.00 |
| Dec 31, 2022 | 395,000.00 |
| Sep 30, 2022 | 396,000.00 |
| Jun 30, 2022 | 421,000.00 |
| Mar 31, 2022 | 390,000.00 |
| Dec 31, 2021 | 366,000.00 |
| Sep 30, 2021 | 413,000.00 |
| Jun 30, 2021 | 269,000.00 |
| Mar 31, 2021 | 256,000.00 |
| Dec 31, 2020 | 291,000.00 |
| Sep 30, 2020 | 311,000.00 |
| Jun 30, 2020 | 321,000.00 |